Development and Molecular Evaluation of Novel 1,3-Disubstituted 1H-furo[2,3-c]pyrazol-4-ols: Synthesis, Characterization, ADMET, and Molecular Docking Studies.

introductionThe development of efficient multicomponent reactions (MCRs) has emerged as a powerful strategy for the rapid synthesis of bioactive heterocyclic scaffolds. In this study, we aimed to design and synthesize a new series of 1,3-disubstituted 1H-furo[2,3-c]pyrazol- 4-ol derivatives, a class of fused heterocycles known for their broad pharmacological potential.

methodsThe target compounds were synthesized via a multicomponent condensation reaction of tetronic acid with phenylhydrazine and various substituted aldehydes in the presence of ammonium acetate. The reactions were conducted under mild conditions, yielding the desired furopyrazole derivatives in satisfactory to good yields. Subsequently, molecular docking and ADMET analyses were performed to predict the pharmacological and pharmacokinetic properties of the synthesized molecules.

resultsThe optimized MCR protocol provided a versatile and reproducible synthetic route to structurally diverse 1H-furo[2,3-c]pyrazol-4-ol derivatives. Molecular docking results revealed that compounds 4a and 4g exhibited the strongest binding affinities toward the cancer-associated target protein (PDB ID: 1JFF), forming stable interactions with key residues in the active site. ADMET predictions further confirmed their acceptable pharmacokinetic and drug-likeness profiles. DISCUSSION: The combination of efficient synthesis and computational evaluation highlights the potential of this molecular framework for drug discovery. The strong binding interactions observed for selected derivatives suggest promising anticancer activity, consistent with the known bioactivity of furo- and pyrazole-based systems.

conclusionThis study demonstrates a facile, atom-economical synthetic approach for generating biologically relevant 1H-furo[2,3-c]pyrazol-4-ol derivatives. Theoretical analyses indicate that compounds 4a and 4g are promising candidates for the development of novel, targeted anticancer agents.